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Pathogenic Th1 and Th17 cells specific for 
myelin autoantigens are regarded as critical for 
both initiation and perpetuation of inflamma-
tion in multiple sclerosis and its animal model, 
experimental autoimmune encephalomyelitis 
(EAE; Diveu et al., 2008). Cytokines involved 
in the Th1 and Th17 axes of inflammation are 
detected in active lesions of multiple sclerosis 
patients (Windhagen et al., 1995; Lock et al., 
2002; Kebir et al., 2009) and in the central 
nervous system (CNS) of mice with EAE 
(Langrish et al., 2005). Adoptive transfer stud-
ies indicate that both Th1 and Th17 cells can 
initiate the autoimmune cascade in this disease 
(Stromnes et al., 2008; Kroenke et al., 2008).
Peroxisome proliferator–activated receptors 
(PPARs) are members of the nuclear hormone 
receptor superfamily. This group of ligand-
activated transcription factors regulates diverse 
processes including lipid and glucose homeo-
stasis, cell proliferation and differentiation, and 
inflammation (Straus and Glass, 2007). PPARs 
are considered to be nutritional sensors, as they 
are bound and activated by fatty acid interme-
diates and can thus translate lipid levels into 
altered gene transcription. PPAR- binds oxi-
dized and nitrosylated fatty acids as well as cer-
tain eicosanoids and prostaglandins (Schopfer 
et al., 2005; Shiraki et al., 2005), whereas 
PPAR- and PPAR- have overlapping speci-
ficities for long-chain unsaturated fatty acids 
(Forman et al., 1997; Chawla et al., 2003; 
Hostetler et al., 2005). Upon binding their 
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Peroxisome proliferator–activated receptors (PPARs; PPAR-, PPAR-, and PPAR-) com-
prise a family of nuclear receptors that sense fatty acid levels and translate this information 
into altered gene transcription. Previously, it was reported that treatment of mice with a 
synthetic ligand activator of PPAR-, GW0742, ameliorates experimental autoimmune 
encephalomyelitis (EAE), indicating a possible role for this nuclear receptor in the control of 
central nervous system (CNS) autoimmune inflammation. We show that mice deficient in 
PPAR- (PPAR-/) develop a severe inflammatory response during EAE characterized by a 
striking accumulation of IFN-+IL-17A and IFN-+IL-17A+ CD4+ cells in the spinal cord. 
The preferential expansion of these T helper subsets in the CNS of PPAR-/ mice occurred 
as a result of a constellation of immune system aberrations that included higher CD4+ cell 
proliferation, cytokine production, and T-bet expression and enhanced expression of IL-12 
family cytokines by myeloid cells. We also show that the effect of PPAR- in inhibiting the 
production of IFN- and IL-12 family cytokines is ligand dependent and is observed in both 
mouse and human immune cells. Collectively, these findings suggest that PPAR- serves as 
an important molecular brake for the control of autoimmune inflammation.
© 2010 Dunn et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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In this paper, we show that PPAR-/ mice exhibit en-
hanced Th cell expansion and cytokine production during 
EAE, as compared with WT mice, resulting in the enhanced 
accumulation of IFN-+/IL-17A and IFN-+/IL-17A+ 
CD4+ cells in the spinal cord and more severe demyelination. 
Moreover, we found that the PPAR- ligand GW0742 in-
hibits the production of IFN- and IL-12 family members in 
both mouse and human immune cells. Together, these find-
ings suggest that PPAR- serves as an important molecular 
brake for the control of CNS autoimmune inflammation.
RESULTS AND DISCUSSION
PPAR- limits the development of CNS inflammation  
during EAE
To investigate the role of endogenously activated PPAR- in 
CNS autoimmunity, we compared the clinical course of EAE 
in WT versus PPAR-/ mice. Upon immunization with 
myelin oligodendrocyte glycoprotein (MOG) p35-55 in CFA, 
WT mice developed classical relapsing-remitting EAE (Fig. 1, 
a and b). In comparison, PPAR-/ mice exhibited a more 
severe course of classical EAE, characterized by persistent 
hindlimb weakness (Fig. 1, a and b). Indeed, one of the main 
clinical features that distinguished WT and PPAR-/ mice 
was that a lower frequency of mice in the PPAR-/ group 
fully recovered to score 0 after the initial acute phase (Table I). 
This phenotype was observed in PPAR-/ mice of both 
ligands, PPARs in complex with 9-cis retinoic acid recep-
tor (RXR) either activate or repress gene transcription. 
PPAR/RXR heterodimers transactivate expression of a wide 
array of genes involved in glucose and lipid metabolism by 
binding to PPAR-responsive elements in gene promoter re-
gions (Straus and Glass, 2007). In immune cells, PPARs have 
a second function of negative regulation of AP-1 and NF-
B–dependent transcriptional activity, a mechanism which 
has been termed ligand-dependent transrepression (Straus and 
Glass, 2007).
PPARs are also activated by several synthetic drugs that are 
currently prescribed or are in clinical trials for the treatment 
of type II diabetes and dyslipidemia (thiazolidinediones for 
PPAR-, fibrates for PPAR-, and GW0742 and GW501516 
for PPAR-; Straus and Glass, 2007). Treatment of mice with 
these drugs ameliorates EAE (Feinstein et al., 2002; Lovett-
Racke et al., 2004; Polak et al., 2005). The PPAR- agonist 
pioglitazone suppresses EAE by inhibiting the T cell produc-
tion of IL-17A (Klotz et al., 2009) and the production of IL-12 
and IL-23 by peripheral and CNS-resident myeloid cells 
(Storer et al., 2005). In contrast, PPAR- appears to inhibit 
inflammation by shifting Th responses from Th1 to Th2 (Jones 
et al., 2003; Dunn et al., 2007; Gocke et al., 2009). How the 
PPAR- agonist GW0742 functions to attenuate EAE is not 
clear. The role of endogenously activated PPAR- in the con-
trol of CNS inflammation is also unknown.
Figure 1. PPAR-/ mice develop hyperacute EAE. EAE was induced in WT or PPAR-/ female (a) or male (b–e) mice (n = 8–10/group).  
(a and b) Mean ± SEM clinical scores of mice at various times after immunization. Results are representative of two to three experiments. (c–e) Paraffin sections 
of spinal cord and brain were prepared from PPAR-/ and WT mice at the time of first remission and were stained with H&E and luxol fast blue.  
d and e show representative sections (bar, 50 µM); c shows the mean + SEM number of inflammatory foci; g shows the regional distribution of parenchy-
mal lesions. (f) Mononuclear cells were isolated from spinal cords of WT or PPAR-/ mice (n = 3/group) at 4 d after the onset of clinical signs, and then 
they were pooled and counted. Cells were stained with antibodies specific for cell surface markers as indicated and the percentage of each subset in the 
live CD45+ gate is shown. Values are mean + SEM numbers from four experiments. *, significantly different from WT.
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IL-17A–producing cells between these two groups (Fig. 2, 
a and b), we did observe a trend for higher amounts of CD4+ 
cells that coproduced both IFN- and IL-17A in PPAR-/ 
spinal cords (629 ± 167 in PPAR-/ vs. 181 ± 49 in WT, 
P = 0.06, n = 3 experiments; Fig. 2 c). Recent studies suggest that 
this Th subset is expanded by IL-23 and is highly pathogenic in 
the acute phase of EAE (Axtell et al., 2006; Kebir et al., 2009).
Next, we investigated whether MOG p35-55–reactive 
Th1 cells also underwent preferential expansion in the periph-
ery of PPAR-/ mice during EAE. We harvested spleens 
from WT and PPAR-/ mice at 8 d after immunization and 
examined the recall proliferation and cytokine production in 
response to MOG p35-55 stimulation. Consistent with spinal 
cord findings, we found that splenocytes from PPAR-/ 
mice produced higher levels of IFN-, IL-17A, and TNF in re-
sponse to peptide stimulation as compared with WT counter-
parts (Fig. 2 d). We also detected higher frequency of IFN-+ 
IL-17A+CD4+ cells in PPAR-/ versus WT splenocytes 
by intracellular cytokine analysis (6.6 ± 1.5 in PPAR-/ vs. 
3.0 ± 1.3 in WT, P = 0.02, n = 4 experiments). In addition, 
PPAR-/ MOG p35-55–reactive splenocytes proliferated 
more robustly than WT cells (Fig. 2 e). In contrast, the serum 
titers of MOG p35-55–specific IgM or IgG were not different 
between WT and PPAR-/ during EAE (Fig. 2 f). Thus, 
the more severe CNS inflammatory response in PPAR-/ 
mice correlated more with the enhanced expansion and CNS 
infiltration of IFN-– and IL-17A–producing CD4+ cells.
PPAR- limits CD4+ cell expansion and effector  
cytokine production
To determine whether the enhanced T cell autoimmunity in 
PPAR-/ mice was a result of intrinsic differences in CD4+ 
cells, we contrasted the cytokine profiles of WT and PPAR-/ 
naive (CD62L+) CD4+ cells in response to ex vivo stimulation 
sexes (Fig. 1, a and b) but appeared more prominently in males 
(Table I). Thus, males were used for subsequent experiments.
To gain insight into why EAE failed to remit in PPAR-/ 
mice, we sacrificed male WT and PPAR-/ mice together 
at the time when WT mice displayed the first improvement of 
clinical signs and conducted a histological analysis of the brain 
and spinal cord. As compared with WT mice, PPAR-/ mice 
displayed more inflammatory foci in the CNS (Fig. 1, c and d 
vs. e). The majority of parenchymal lesions were detected in the 
spinal cord in both groups; however, only in PPAR-/ mice 
were there lesions in the cerebrum and cerebellum (Fig. 1 g). As 
compared with the WT group, PPAR-/ mice also exhib-
ited higher vacuolation/demyelination scores (mean ± SEM = 
2.4 ± 0.4 in PPAR-/ vs. 1.2 ± 0.2 in WT, P = 0.04). Con-
sistent with histological findings, a higher number of CD4+ and 
CD19+ cells were recovered from spinal cords of PPAR-/ 
versus WT mice during the acute phase of EAE (Fig. 1 f). 
Together, these results indicate that the more severe EAE that 
developed in PPAR-/ mice was the result of immune-
 mediated myelin and axon damage.
PPAR- inhibits Th1 and Th17 autoimmunity  
in the periphery and CNS
Because Th1 and Th17 cells can initiate and perpetuate the 
CNS inflammatory cascade in EAE (Diveu et al., 2008), we 
next examined the cytokine production by CNS-infiltrating 
CD4+ cells during this disease. Mononuclear cells were isolated 
from spinal cords of WT and PPAR-/ mice at 4 d after the 
onset of clinical signs, and the production of IFN- and IL-17A 
by CD4+ cells was determined by intracellular cytokine stain-
ing. This analysis revealed the presence of a higher number 
(Fig. 2 a) and frequency (Fig. 2 b) of IFN-–producing CD4+ 
cells in spinal cords of PPAR-/ versus WT mice. Although 
we did not detect a difference in the number or frequency of 
Table I. Clinical features of EAE in male and female WT and PPAR-/ mice.
Clinical feautres WT male PPAR-/ male WT female PPAR-/ female
Maximum score
Experiment 1 2.9 (0.5) 2.9 (0.2) 2.4 (0.3) 3.3 (0.6)
Experiment 2 2.9 (0.1) 2.9 (0.2) 3.3 (0.2) 3.3 (0.3)
Death from disease
Experiment 1 1/9 0/7 0/9 2/6
Experiment 2 0/10 2/9 0/9 1/11
Incidence
Experiment 1 8/9 7/7 9/9 6/6
Experiment 2 10/10 9/9 9/9 11/11
Day of onset
Experiment 1 12.4 (0.5) 13.6 (1.0) 14.6 (1.4) 12.3 (0.4)
Experiment 2 8.3 (0.1) 10.9 (0.8)a 11.0 (0.3) 11.4 (0.8)
Number of mice remitting to score 0
Experiment 1 7/7 (100%) 2/7 (28%) 9/9 (100%) 3/6 (50%)
Experiment 2 8/10 (80%) 1/9 (11%) 8/9 (89%) 6/11 (54%)
Values are means + SEM.
aSignificant difference from sex-matched WT counterpart
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with anti-CD3 and anti-CD28. We found that a higher 
proportion of naive PPAR-/CD4+ T cells than WT 
CD4+ cells differentiated to become cytokine-producing cells 
in response to stimulation (Fig. 3, a and b). IFN-+IL-17A 
cells were detected at a higher frequency in cultures of 
PPAR-/ versus WT cells under Th0 conditions (Fig. 3 a), 
whereas both IFN-IL-17A+ and IFN-+IL-17A+ copro-
ducing subsets were more prominent in PPAR-/ cultures 
after activation under Th17-skewing conditions (Fig. 3 b). 
Higher production of IFN- and IL-17A by PPAR-/CD4+ 
cells was also detected at the protein level by ELISA (Fig. 3, 
c and d) and at the mRNA level via real-time PCR (Fig. 3, 
e and f). The enhanced cytokine production by PPAR-/ 
CD4+ cells was not limited to IFN- and IL-17A, as IL-2 
and IL-10 were also elevated in PPAR-/ cultures (Fig. 3, 
c and d). These results indicate that the enhanced Th cyto-
kine production and dual IFN-/IL-17A production that we 
observed in PPAR-/ mice was in part a result of intrinsic 
differences in CD4+ cells.
Because related PPAR family members inhibit RORT 
and T-bet expression (Jones et al., 2003; Klotz et al., 2009), 
we contrasted the mRNA levels of these transcription factors 
in PPAR-/ versus WT CD4+ cells. Although RORT 
expression was not different between these two groups, 
T-bet transcripts were markedly enhanced in PPAR-/ as 
compared with WT CD4+ cells at 48 h after stimulation 
(Fig. 3 h). Given results that T-bet supports expansion of both 
Th1 and Th17 cells and is more highly expressed in double-
positive (IFN-+IL-17+) versus IFN- single-positive CD4+ 
cells (Yang et al., 2009), the higher levels of this transcription 
factor may explain the propensity of PPAR-/CD4+ cells for 
dual IFN-/IL-17A production. Nevertheless, our finding 
that T-bet mRNA expression trailed the peak in IFN- 
mRNA indicates that it is not the sole cause of enhanced cyto-
kine production by PPAR-/CD4+ cells.
Consistent with the reported role for PPAR- in regulat-
ing cell growth (Peters and Gonzalez, 2009), we also ob-
served that PPAR-/CD4+ cells proliferated to a greater 
extent than WT CD4+ cells in response to anti-CD3 and 
anti-CD28 stimulation (Fig. 4 a). Interestingly, spleens taken 
directly from nonimmunized PPAR-/ mice exhibited a 
higher frequency of CD4+ cells that displayed a memory 
(CD44highCD62L) or activated (CD69+) CD4+ phenotype 
(Fig. 4, c and d). In contrast, we did not detect differences in 
the proliferation rates of WT and PPAR-/ B cells (Fig. 4 b). 
Collectively with cytokine findings, these results indicate that 
PPAR- negatively regulates the activation state and effector 
function of CD4+ cells.
Finally, to confirm that a defect of PPAR- in the 
T cell compartment was causal to the hyperexpansion of 
MOG p35-55–reactive CD4+ cells that we observed in 
Figure 2. PPAR-/ mice exhibit higher Th cytokine production 
during EAE. (a and b) Mononuclear cells were isolated from spinal cords 
of WT or PPAR-/ mice at 4 d after the onset of clinical signs, and then 
they were pooled (n = 3/group) and processed for intracellular cytokine 
staining. The number (a) and frequency (b) of CD4+ mononuclear cells 
that had intracellular accumulation of IFN- (IFN-+IL-17A and IFN-+ 
IL-17A+) or IL-17A (IL-17A+ IFN-+ and IL-17A+ IFN-) are shown.  
(c) Representative FACs plot of IFN- and IL-17A staining in CD4+ gate.  
(d and e) Splenocytes from male age-matched WT or PPAR-/ mice were 
harvested at 8 d after immunization and were stimulated ex vivo with 
MOG p35-55. Cytokines (d) were measured in culture supernatants using 
ELISA. Proliferation (48 h; e) was measured by [3H]-thymidine incorpora-
tion assay. Values are means + SEM of triplicate culture wells. Data in  
a–e are representative of three experiments. (f) Serum was collected from 
WT and PPAR-/ mice during EAE. Titers of MOG p35-55–specific IgM 
and total IgG were determined by ELISA. Values are absorbance measure-
ments of individual mice from two experiments that contained n = 5 and 
n = 11 mice/group. *, significantly different from WT.
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togenicity of transferred CD4+ cells. Spleno-
cytes from the Rag1/ mice reconstituted 
with the PPAR-/CD4+ cells exhibited 
higher IFN- and IL-17A production as 
compared with those transferred with WT 
CD4+ cells (Fig. S1 a). Although only a small 
fraction (25%) of mice in both groups suc-
cumbed to EAE, more WT B6.Rag1/ than 
PPAR-/B6.Rag1/ mice developed a 
relapsing-remitting course (four of four of WT vs. one of 
four PPAR-/B6.Rag1/; Fig. S1 b). These results in-
dicate that PPAR- acts in the CD4+ cell compartment to 
limit expansion of Th1 and Th17 cells and to dampen CNS 
inflammation during EAE.
PPAR- inhibits expression of IL-12 family cytokines
Both IFN-+/IL-17A and IFN-+/IL-17A+ CD4+ cells 
were detected in spinal cords of PPAR-/ mice during 
EAE. The former Th subset is induced by IL-12, whereas 
the latter subset is expanded by IL-23 (Awasthi et al., 2009; 
McGeachy et al., 2009). Given results that the related 
nuclear receptor PPAR- negatively regulates IL-12p40 
(common to IL-12 and IL-23; Storer et al., 2005), we in-
vestigated whether myeloid cells from PPAR-/ mice 
have a higher propensity to produce this or other IL-12 
family cytokines. Indeed, we found that splenic cd11b+ cells 
and peritoneal macrophages from PPAR-/ mice pro-
duced higher levels of IL-12p40 as compared with WT 
counterparts (Fig. 5, a and b). A small amount of IL-12p70 
(p35/p40 heterodimer) was also detected in supernatants of 
PPAR-/ cells at levels that were higher than those ob-
served in WT. In contrast, we did not detect a consistent 
difference in the production of other cytokines between 
these groups. Similar to ELISA findings, we also observed 
that the mRNA expression of the IL-12 family members 
IL-12p40, IL-23p19, and IL-12p35 were markedly elevated 
in PPAR-/ versus WT splenic cd11b+ cells after LPS stim-
ulation (Fig. 5 c). Because myeloid cells drive the expansion 
of Th cells in the CNS during EAE (Bailey et al., 2007), 
PPAR-/ during EAE, we made chimeras by reconsti-
tuting B6.Rag1/ mice with either WT or PPAR-/ 
CD4+ T cells. We then immunized these mice with MOG 
p35-55/CFA, and examined the expansion and encephali-
Figure 3. PPAR- limits cytokine production by 
CD4+ cells. (a–c) Naive CD4+ cells were isolated from the 
spleens of WT or PPAR-/ mice and stimulated with 
anti-CD3 and anti-CD28 under Th0-skewing (a, c, e, and g) 
or Th17-skewing (b, d, f, and h), conditions. After 4 d  
of culture, CD4+ cells were processed for intracellular 
cytokine staining. (a and b) Representative FACs plots of 
events in the CD4+ gate. (c and d) Cytokine levels in cul-
ture supernatants after 48 h of culture under Th0-skewing 
(c) or Th17-skewing (d) conditions. (e–h) mRNA levels  
of IFN- and T-bet (Th0 conditions) or IL-17A and RORt 
(Th17 conditions; relative to -actin mRNAs) were deter-
mined using real-time PCR. *, significantly different from 
WT. Values are means + SEM of triplicate cultures (c and d) 
or triplicate reactions (e–h). Data are representative of 
two to five experiments.
Figure 4. CD4+ T cells from PPAR-/ mice are hyperresponsive. 
Naive CD4+ (a) or CD19+ (b) cells were isolated from the spleens of WT or 
PPAR-/ mice and were stimulated as indicated. Proliferation of these 
cells was measured using a [3H]-thymidine incorporation assay. Values are 
means + SEM of triplicate cultures. (c and d) Splenocytes were harvested 
from nonimmunized WT or PPAR-/ mice. The frequency of CD4+ cells 
that displayed a memory (CD44high and CD62Llow; c) or activated (CD69+ or 
CD25+; d) phenotype in each group was determined. In d, values represent 
mean + SEM frequencies of n = 3–4 mice/group. Data in a–d are repre-
sentative of two experiments. *, significantly different from WT.
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the specific PPAR- agonist GW0742. We used 
up to 1 µM of this drug because preliminary ex-
periments indicated that GW0742 has off-target 
effects at ≥1-µM concentrations. These initial 
experiments revealed that GW0742 triggered 
an increase in Th1 cytokine production by WT CD4+ cells 
(Fig. 6 a). These results were unexpected given our results in 
PPAR-/ mice; however, they were consistent with pre-
vious results of GW0742 on Th1 cytokine production during 
EAE (Polak et al., 2005).
Because bovine serum is a potential source of several 
endogenous PPAR- ligands, we posited that the failure of 
GW0742 to dampen Th1 cytokine production was because 
PPAR- was already saturated with a serum-derived ligand. 
To test this possibility, we repeated the experiment using 
serum-free X-vivo 20 media. Under these conditions, GW0742 
had the expected effect of decreasing the production of IFN- 
by WT but not by PPAR-/ CD4+ cells (Fig. 6, b–d). 
this finding that PPAR-/ macrophages have a higher 
propensity to produce IL-12 family cytokines may further 
explain the preferential accumulation of IFN-+/IL-17A 
and IFN-+/IL-17A+ CD4+ cells in the CNS of PPAR-/ 
mice during this disease.
PPAR- suppresses IFN- and IL-12 production  
in a ligand-dependent manner
PPAR- is reported to have both ligand-dependent 
and -independent actions in vivo (Straus and Glass, 2007). 
To test how the ligand dependency of PPAR- affects Th cell 
production, we stimulated WT or PPAR-/ CD4+ T cells 
with anti-CD3 and anti-CD28 in the presence or absence of 
Figure 5. PPAR- negatively regulates expression of 
IL-12 family cytokines. Splenic CD11b+ cells (a and c) or 
peritoneal macrophages (b) were isolated from adult age-
matched WT and PPAR-/ mice and were cultured with 
10 ng/ml LPS. (a and b) Supernatants were collected at 24 h 
for cytokine measurement by ELISA. (c) Cells were har-
vested at 0, 1, 3, or 5 h after stimulation for collection of 
RNA for real-time PCR measurement of p40, p35, or p19 
mRNA expression (relative to -actin). Values represent 
mean + SEM of triplicate cultures (a and b) or reactions (c). 
*, significantly different from WT. Results are representa-
tive of three experiments.
Figure 6. GW0742 suppresses IFN- and IL-12 family cytokines in a PPAR-–dependent manner. CD4+ cells (a–e) or peritoneal macrophages  
(f) were stimulated in the presence of 100 nM GW0742 or vehicle of equal volume. Cells were cultured in complete RPMI (a) or X-vivo 20 serum-free  
media (b–f). CD4+ cells were stimulated with anti-CD3 under Th0-skewing (a–d) or Th17-skewing (e) conditions, whereas peritoneal macrophages were 
stimulated with LPS. Cytokine production was measured after 24 or 48 h of culture by ELISA and intracellular staining was conducted after 4 d of culture 
as in Fig. 3. Values represent means + SEM of triplicate cultures. *, significantly different from WT. †, significantly different from vehicle counterpart.  
Results are representative of three experiments.
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Concluding remarks
This study provides new evidence that PPAR- is an important 
negative regulator of CNS autoimmune inflammation. We 
found that mice deficient in this nuclear receptor exhibit a se-
vere course of EAE characterized by a preferential accumulation 
of IFN-+IL-17A and IFN-+IL-17A+ CD4+ subsets in the 
CNS. This appeared to occur as a result of several immune aber-
rations that included a hyperresponsive CD4+ T cell population 
and higher IL-12 family cytokine production by myeloid cells. 
We also found that the PPAR- ligand GW0742 inhibits the 
production of IFN- and IL-12p40 by both mouse and human 
immune cells, indicating that these immune regulatory effects of 
PPAR- are ligand dependent and conserved between mouse 
and man. Taken in this light, our observation of immune phe-
notypic differences between WT and PPAR-/ mice, in the 
absence of treatment with synthetic ligands, suggests that that 
PPAR- likely binds an endogenous ligand to mediate its anti-
inflammatory effects in vivo. Future studies will investigate the 
nature of these ligands as well as the molecular mechanism of 
inhibition of IFN- and IL-12 family cytokines by PPAR-.
MATERIALS AND METHODS
Mice and EAE induction. Mice that have targeted disruption of the last 
exon of PPAR-/ gene containing the ligand-binding and RXR heterodi-
merization domains have been described previously (Peters et al., 2000). 
Homozygote mice express a truncated unstable PPAR- transcript, resulting 
in no detectable PPAR- protein (Peters et al., 2000). These mice, herein re-
ferred to as PPAR-/ mice, were originally on an outbred (129 × B6F1) 
background and were crossed six generations to C57BL/6. PPAR-/ 
pups could not be generated past the sixth generation. Thus, WT and 
mutant colonies were established from the sixth generation. Genotyping of 
PPAR-/ mice and WT counterparts was performed by amplifying a por-
tion of the ligand-binding domain of PPAR- or the neo cassette insert of 
the mutant allele from tail DNA (cycling conditions: 1 min at 94°C, 1 min 
at 60°C, and 1 min at 72°C). Primer sequences were: PPAR- forward, 
5-CAGGATGTCCTTCCACAGAGACAG-3; PPAR- reverse, 5-TTA-
GCCACTGCATCATCTGGG-3; and neo cassette, 5-GCAATCCAT-
CTTGTTCAATGGC-3.
EAE was induced in PPAR-/ mice (8–12 wk of age) and age-
matched WT counterparts via subcutaneous immunization with 100 µg 
MOG p35-55 in an emulsion with CFA (Dunn et al., 2007). Mice were also 
Similarly, GW0742 suppressed the production of IL-12p40 
in a PPAR-–specific fashion by macrophages (Fig. 6 f). Inter-
estingly, treatment with GW0742 did not lower the produc-
tion of IL-17A by WT T cells as detected by ELISA (Fig. 6 e), 
indicating that the enhanced production of IL-17A by 
PPAR-/ CD4+ cells was likely related to general effects 
of PPAR- on T cell expansion.
Transcriptional regulation of IFN- is complex, as it is 
dictated by the interaction of functional genomic elements 
acting as far as 50 kb from this gene (Aune et al., 2009). 
Comparatively, the LPS-induced transcription of IL-12p40 is 
more straightforward, as it involves the binding of well char-
acterized transcription factors (i.e., NF-B) to genomic ele-
ments in the proximal promoter of this gene (Murphy et al., 
1995). We thus pursued studies of the IL-12p40 promoter 
to gain insight into the mechanism of ligand inhibition of 
cytokine production. We observed that GW0742 repressed 
IL-12p40 promoter activity in RAW264.7 cells that were 
transfected with an IL-12p40/luciferase reporter construct 
(Fig. S2). This ligand effect was dose and PPAR- dependent 
(Fig. S2). This result indicates that PPAR- works via a 
mechanism of transcriptional repression to regulate IL-12p40 
gene expression.
PPAR- inhibits the production of IFN- and IL-12 family 
cytokines by PBMCs
Given that GW0742 is a ligand agonist of both mouse and 
human PPAR-, we investigated whether this drug modu-
lates cytokine production by human immune cells. We ob-
tained PBMCs from three male healthy donors and then 
cultured these cells in serum-free media containing either 
100 nM GW0742 or vehicle control in the presence of either 
anti-CD3 and anti-CD28 or LPS. Similar to findings in the 
mouse system, we found that 100 nM GW0742 selectively re-
duced the production of IFN- by PBMCs in response to anti-
CD3 and anti-CD28, and it blunted the LPS induction of 
IL-12p40 and IL-23 (Table II). These effects were observed in 
three of three donors.
Table II. Cytokine production by human PBMCs treated with 100 nM GW0742
Stimulus Donor 1 Donor 2 Donor 3
Vehicle GW0742 Vehicle GW0742 Vehicle GW0742
-CD3 and -CD28
IL-2 122 (7) 160 (8)a 178 (5) 200 (11) 92 (11) 93 (4)
IL-17A 21 (2) 25 (1) 14 (1) 16 (5) 16 (1) 14 (1)
TNF 140 (12) 113 (13) 491 (17) 400 (88) 1,019 (50) 1,178 (50)
IFN- 1,231 (213) 716 (33)a 4,205 (129) 3,125 (271)a 3,087 (111) 2,547 (97)a
LPS
IL-12p40 7,160 (152) 4,541 (162)a 5,497 (264) 3,203 (328)a 8,881 (367) 5,562 (318)a
IL-23 3,581 (54) 2,507 (109)a 2,262 (41) 1,450 (50)a 3,775 (136) 2,508 (124)a
IL-12p70 322 (38) 275 (36) 1,486 (145) 991 (85) a 1,195 (187) 1,335 (157)
Values are means + SEM of cytokine levels (pg/ml) in triplicate cultures.
aSignificant difference from vehicle control cultures using a Student’s t test (P = 0.05, two-tailed).
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FACS staining of cell subsets in the spleen and CNS. FACs staining 
of splenocyte and CNS mononuclear cells was done using BD antibodies 
and protocols unless otherwise noted. Antibodies directed against the fol-
lowing mouse cell surface antigens were used: CD4, CD8, CD19, CD11b, 
CD11c, CD44, CD45, CD62L, and F4/80 antigen (AbD Serotec). Intracel-
lular staining of mouse FoxP3 was performed using a kit from eBioscience. 
For intracellular cytokine staining, cells were stimulated for 4 h with 10 ng/ml 
PMA and 750 nM ionomycin in the presence of GolgiStop to cause intracel-
lular accumulation of cytokines. Cells were then stained with anti-CD4 and 
fixable aqua live/dead dye (Invitrogen) before fixation, permeabilization, 
and intracellular staining for mouse anti–IFN- and IL-17A. Data were ac-
quired using a Flasher II cell sorter (BD) or LSRII analyzer and the fre-
quency of CD45+/CD4+ cells expressing IFN- and IL-17 was analyzed 
using FlowJo software (Tree Star, Inc.).
Culture of isolated myeloid and Th cell populations. CD11b+ or 
CD19+ cells were isolated by positive selection and CD4+ cells by negative 
selection using reagents (Miltenyi Biotec). The naive CD4+ fraction was 
further fractionated using CD62L+ magnetic beads provided in the naive 
mouse CD4+ isolation kit (Miltenyi Biotec). Peritoneal macrophages were 
harvested from the peritoneum of mice at 3 d after i.p. injection with thio-
glycollate. These cells were washed, plated in flat-bottom plates (2 × 105/well), 
and allowed to rest overnight (with vehicle or GW0742) before stimula-
tion with LPS. All cells were resuspended in complete RPMI or in 
X-vivo 20 serum-free media (Lonza; serum-free media also contained 2 mM 
L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 
100 U/ml penicillin, 0.1 mg/ml streptomycin, and 0.5 µM 2-mercaptoethanol). 
T cells were cultured with 0.1–0.5 µg/ml of plate-bound anti-CD3 (clone 
145-2C11; BD) and -CD28 (clone 37.51; BD) under Th0-skewing condi-
tions (no added cytokines) or Th17-skewing conditions (20 ng/ml of mouse 
recombinant IL-6, 3 ng/ml of human recombinant TGF-, and 10 µg/ml of 
anti–IFN- (XMG1.2). Peritoneal macrophages or splenic cd11b+ cells were 
cultured in flat-bottomed 96-well plates with 1–100 ng/ml LPS. Cytokines 
were measured in the supernatants of cultured cells at 24–72 h using com-
mercial ELISA kits.
Proliferation. Proliferation rate of T cells and B cells was measured as de-
scribed previously (Dunn et al., 2007).
Real-time PCR. RNA was extracted from naive CD4+ T cells immedi-
ately after isolation or after 24 h of culture using Absolutely RNA kits (Agi-
lent Technologies). Real-time PCR was conducted using the standard curve 
method, using SYBR Green reagents (QIAGEN) and the following specific 
primer sets: IL-12p40 forward, 5-TCCCCATTCCTACTTCTCCCTC-3; 
IL-12p40 reverse, 5-GGAACGCACCTTTCTGGTTACA-3; IL-12p35 
forward, 5-CACGCTACCTCCTCTTTTTG-3; IL-12p35 reverse, 5-CAG-
CAGTGCAGGAATAATGTT-3; IL-23p19 forward, 5-AATCTCTG-
CATGCTAGCCTGG-3; IL-23p19 reverse, 5-GATTCATATGTCCC-
GCTGGTG-3; T-bet forward, 5-AATGCCGCTGAATTGG-3; T-bet 
reverse, 5-CGTGACTGTAGTTCGGG-3; RORT forward, 5-AGAT-
TGCCCTCTACACG-3; RORT reverse, 5-GGCTTGGACCAC-
GATG-3; -actin forward, 5-TGTCCCTGTATGCCTCTGGT-3; and 
-actin reverse 5-CACGCACGATTTCCCTCTC-3. IFN- and IL-17 
mRNAs were measured using one-step EZ Taqman reagents and Taqman 
primer probe sets (Applied Biosystems). Expression was normalized to either 
-actin or 18S ribosomal RNA (primers from SuperArray).
IL-12p40 promoter analysis. The RAW264.7 mouse macrophage cell 
line was maintained in RPMI1640 medium supplemented with 10% fetal 
bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. Cells were 
transfected using Lipofectamine 2000 (Invitrogen) and were cultured in 
6-well plates in low-serum (0.5% FBS) media containing penicillin and strep-
tomycin. The luciferase reporter DM-703, in which luciferase transcription 
is directed by a mouse IL12p40 promoter fragment extending to 703, was 
obtained from K.M. Murphy (Washington University School of Medicine, 
injected intravenously with 50 ng Bordetella pertussis toxin (BD) at the time 
of, and 2 d after, immunization. Mice (n = 8–10/group) were examined 
daily for clinical signs of EAE and were scored on a five point scale: 0, no 
clinical disease; 1, limp tail; 2, hindlimb weakness; 3, complete hindlimb pa-
ralysis; 4, hindlimb paralysis plus some forelimb paralysis; and 5, moribund or 
dead. We found that clinical phenotype of PPAR-/ mice was pro-
nounced in males. Thus, we conducted all subsequent experiments in male 
mice. Animal protocols were approved by the Division of Comparative 
Medicine at Stanford University and animals were maintained in accordance 
with the guidelines of the National Institutes of Health.
MOG p35-55–specific Th responses. At 8 d after immunization (in EAE 
experiments), spleens were recovered from nonsick immunized mice (n = 3 
mice/group) and were dissociated into a single cell suspension. Red blood 
cells were lysed and splenocytes were cultured in 96-well plates (0.5 × 106 
cells/well) with 0–25 µg/ml MOG p35-55 in complete RPMI (RPMI 1640 
supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM 
nonessential amino acids, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.5 µM 
2-mercaptoethanol, and 10% fetal calf serum). Culture supernatants were 
harvested at 24–72 h after stimulation for cytokine measurement by ELISA 
(BD, R&D Systems, and eBioscience kits).
Rag transfer experiments. CD4+ cells were isolated from spleens of 
male PPAR-/ mice (n = 10 mice/group), pooled together, and 7–10 × 106 
of these cells were injected intravenously into B6.Rag1/ recipients (The 
Jackson Laboratory). B6.Rag1/ transferred with WT CD4+ cells served 
as controls. EAE was induced in these mice at 48 h after transfer as de-
scribed previously (Dunn et al., 2007). Approximately 25% of mice in each 
group developed clinical signs. Nonsick mice were used to investigate the 
role for T cell–expressed PPAR- in the regulation of MOG p35-55 
splenocyte responses.
MOG p35-55–specific IgG and IgM responses. Mice were bled at day 
28 of disease. MOG p35-55–specific antibodies were detected in the sera of 
mice using an ELISA assay. In brief, plates were coated overnight at 4°C 
with 10 µg/ml MOG p35-55 peptide and then blocked with 3% fetal calf 
serum before serial probing with sera (1:100 diluted, 2 h), followed by a 1-h 
incubation with horseradish peroxidase–conjugated goat anti–mouse IgG or 
IgM (SouthernBiotech). Plates were washed three times with 0.5% PBS 
containing Tween 20 between each step. Horseradish peroxidase conjugates 
were detected using tetramethylbenzidine substrate. Absorbances were mea-
sured at 450 nm and background levels were subtracted.
Histopathology. Brains and spinal cords were dissected from male mice 
(n = 5/group), fixed in 10% formalin in PBS, and embedded in a single paraffin 
block. 6–10-µm-thick sections were stained with hematoxylin and eosin and 
luxol fast blue. The number of meningeal and parenchymal inflammatory 
foci was counted in brain and spinal cord sections by a trained neuropatholo-
gist who was blinded to the clinical and treatment status of the animal. A de-
myelination/vacuolation score was also assigned to each specimen that 
ranged in severity from 0 (absence of demyelination/vacuolation) to 4 (severe 
demyelination/vacuolation).
Isolation of CNS mononuclear cells. CNS mononuclear cells were iso-
lated from mice (n = 3 mice/group) at 5 d after the onset of EAE. Mice were 
anaesthetized (80–100 mg/kg ketamine hydrochloride: 10 mg/kg xylazine) 
and perfused with PBS containing 5 U/ml heparin. Spinal cords were pooled 
together (n = 3), scissor minced into Hank’s buffered saline, and then digested 
for 45 min at 37°C with 300 U/ml Clostridial collagenase type IV (Roche) 
and 1 mg/ml DNase (Sigma-Aldrich). After digestion, the spinal cord tissue 
was dissociated through a 70-µm sieve. This filtrate was centrifuged and the 
pellet containing the mononuclear cells was resuspended in 30% Percoll 
(GE Healthcare). This suspension was underlaid with 70% Percoll and centri-
fuged at 1,800 rpm for 10 min. Mononuclear cells were collected from the 
30/70% interface, washed twice, and suspended in complete RPMI.
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St. Louis, MO; Murphy et al., 1995). The plasmid pCMV-gal was cotrans-
fected along with the luciferase reporter as an internal control for transfec-
tion efficiency and for the specificity of the effects observed. The plasmid 
pCMX-PPAR- was used for expression of mouse PPAR- (Forman et al., 
1997). To determine the effect of GW0742 on promoter activity, cells were 
pretreated with GW0742 for 1 h before addition of LPS (final concentration, 
100 ng/ml). Incubation was continued for 6 h, after which the cells were 
harvested for luciferase and -galactosidase assays.
Culture of human PBMCs. PBMCs were isolated from peripheral blood 
of three healthy donors using Ficoll gradient. These cells were resuspended 
in X-vivo 15 media containing 2 mM L-glutamine, 1 mM sodium pyruvate, 
0.1 mM nonessential amino acids, 100 U/ml penicillin, 0.1 mg/ml strepto-
mycin, and 0.5 µM 2-mercaptoethanol. Either 100 nM of GW0742 or an 
equal volume of vehicle was added to cells, and they were plated (2 × 105/
well) in flat-bottomed plates. After 2 h of vehicle or ligand treatment, Dyna-
beads human T cell expander (1 Dynabead for every 10 T cells; Invitrogen) 
or 10 ng/ml LPS was added to cells. Cytokines were measured in culture 
supernatants at 48 or 72 h using IFN-, IL-2, TNF, and IL-17A ELISA kits 
(eBioscience) and an IL-12p40 kit (BD).
Statistical analysis. Data are presented as means + SEM. When data were 
parametric (kurtosis and skewness < 2), a Student’s t test (two-tailed) was 
used to detect between-group differences. When data were nonparametric, 
ranks were compared among groups using a Mann-Whitney U test. A value 
of P ≤ 0.05 was considered significant.
Online supplemental material. Fig. S1 depicts the results from EAE 
studies using Rag/ mice transferred with WT or PPAR-/ CD4+ cells. 
Fig. S2 depicts the results from the IL-12p40 luciferase reporter experiment. 
Online supplemental material is available at http://www.jem.org/cgi/ 
content/full/jem.20091663/DC1.
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